SIMBRINZA is a Ophthalmic Suspension/ Drops in the Human Prescription Drug category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is Brinzolamide; Brimonidine Tartrate.
Product ID | 0078-0904_9524ff62-7850-405a-9b93-311e8dde17ea |
NDC | 0078-0904 |
Product Type | Human Prescription Drug |
Proprietary Name | SIMBRINZA |
Generic Name | Brinzolamide/brimonidine Tartrate |
Dosage Form | Suspension/ Drops |
Route of Administration | OPHTHALMIC |
Marketing Start Date | 2013-05-01 |
Marketing Category | NDA / NDA |
Application Number | NDA204251 |
Labeler Name | Novartis Pharmaceuticals Corporation |
Substance Name | BRINZOLAMIDE; BRIMONIDINE TARTRATE |
Active Ingredient Strength | 10 mg/mL; mg/mL |
Pharm Classes | Carbonic Anhydrase Inhibitor [EPC],Carbonic Anhydrase Inhibitors [MoA],Adrenergic alpha-Agonists [MoA],alpha-Adrenergic Agonist [EPC] |
NDC Exclude Flag | N |
Listing Certified Through | 2021-12-31 |
Marketing Start Date | 2020-08-04 |
NDC Exclude Flag | N |
Sample Package? | N |
NDC | Brand Name | Generic Name |
---|---|---|
0065-4147 | SIMBRINZA | brinzolamide/brimonidine tartrate |
0078-0904 | SIMBRINZA | brinzolamide/brimonidine tartrate |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
SIMBRINZA 85306875 4388553 Live/Registered |
Novartis AG 2011-04-28 |